In the university hospital TUM Klinikum rechts der Isar, drugs against Covid-19 are tested.
In the university hospital TUM Klinikum rechts der Isar, drugs against Covid-19 are tested.
Image: Hiraman
  • Covid-19, Research news
  • Reading time: 2 MIN

Clinical trials on Covid-19 at university hospital TUM Klinikum rechts der IsarMedications against coronavirus in trial

The university hospital is participating in studies on new medications for people suffering from Covid-19. As part of a clinical study, patients can be treated with medications that are still under development. 50 patients infected with the novel Coronavirus are currently being treated at the university hospital TUM Klinikum rechts der Isar.

In a number of clinical studies, scientifically active physicians at the hospital are treating patients suffering from Covid-19 with medications that are still undergoing clinical trials, including the polymerase inhibitor Remdesivir among others. Remdesivir has a direct anti-viral effect and inhibits the reproduction of the virus. Originally developed to treat patients infected with Ebola, it has not yet been approved for clinical use. In laboratory testing the active ingredient has proven effective against the new SARS Coronavirus 2. The international study will investigate the efficacy and safety of the active ingredient in moderately and seriously ill patients. Other medications are undergoing clinical testing in other studies, including further anti-infectives and anti-inflammatory active ingredients.

Central biobanks help improve understanding of the illness

In addition, large clinical registers and central biobanks record data and samples from all patients with Covid-19 treated at the TUM Klinikum rechts der Isar. This will make it easier to understand the illness and contributes to the development of new therapies.

Prof. Bernhard Hemmer, Dean of the TUM School of Medicine, explains: “In addition to our major efforts in the treatment of Covid-19 patients, as a university hospital we are very aware of our special responsibility in research on new possible therapies and in the investigation of new treatment strategies for Covid-19. We are applying the experience we have gained in treatment of a large number of patients in clinical studies and are working with partners from around the world to improve possible treatments.”

Technical University of Munich

Corporate Communications Center

Article at

Prof. Jan Baumbach

Researchers develop software for drug repurposing

Currently, the corona pandemic is dominating the entire social life in Germany and in many other parts of the world. We are working flat out in order to better help the more than one hundred thousand seriously ill people in...

Person wachting at a smartphone

Encryption system for a secure contact tracing app

In the fight against Covid-19, an interdisciplinary research team at the Technical University of Munich (TUM) has developed a model for a contact tracing app that protects personal data. The concept is based on an...

Prof. Wall (r) and Dr. Biehler at work on their virtual lung model.

Computer model enables protective ventilation

The use of mechanical ventilation can save lives – and not just for COVID-19 patients who develop severe respiratory problems. But at the same time, the ventilation pressure puts immense stress on delicate lung tissue....

Staff member of the virology department at TUM evaluating the antibody tests.

Large Antibody Study at the Klinikum rechts der Isar

One of the largest antibody studies against SARS-CoV-2 in Germany has begun at the university hospital Klinikum rechts der Isar at Technical University of Munich (TUM). The employee study is intended to provide data on the...

Professor Ulrike Protzer, director of the Institute of Virology at TUM, joins the state government's expert council.

Prof. Protzer joins expert council on Corona crisis

At a press conference today, Bavaria's Minister President Dr. Markus Söder and Minister of Science and Art Bernd Sibler announced the appointment of an expert council in preparation for upcoming political decisions during...

TUM-Präsident Thomas F. Hofmann

Working together to promote digital learning

For the time being the corona pandemic has made it impossible to hold courses in lecture halls and seminar rooms. Nevertheless TUM wants to make sure that its 43,000 students suffer no serious consequences and they will...

TUM main entrance

Restricted operations extended until 17 April

In response to the continued spread of the virus and the Federal and Bavarian government measures to limit contact among the public, the TUM Board of Management decided to extend the university’s restricted operations, for...

Prof. Ulrike Protzer with colleagues in the laboratory.

Hepatitis B: New therapeutic approach

Researchers at Technical University of Munich (TUM), Helmholtz Zentrum München and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B. The scientists...